Diabesity - novel molecular targets for obesity and type 2 diabetes
Next Member  
Previous Member  
Dr Jörg Hager Dr Jörg Hager
IntegraGen SA
4 rue Pierre Fontaine
Phone: +33 1 60 910 900
DrJörg Hager
Workpackage 5 leader


Since Integragen's founding, it has successfully developed, validated and applied the GenomeHIP™ technology platform for identifying genes associated with complex disease traits.  Since start-up the firm has determined and patented several gene products involved with obesity and autism.

Integragen's GenomeHIP™ overcomes obstacles to the elucidation of genes etiologically associated with complex disease.  Complex diseases are caused by multiple genetic alterations in several different genes.  They are influenced by several factors, including hereditary and environment, and are thought to be an unavoidable consequence of senescence.  Since complex diseases span the gamut of healthcare, they are simply an enormous cost to the world's health care systems.  In short, Integragen's GenomeHIP™ is a 'cheaper, faster, and better' variant of currently performed methods.


Diabesity: Novel molecular targets for obesity and type 2 diabetes
  home | research | publications | members | events | about diabesity | press | links | contact us